เมเว็นคลัด
MAVENCLAD
activeLast updated: 2026-07-29
Product & certifications 1
- FDA 1C15034/63(NC)drugคงอยู่
ตัวยาสำคัญ
- CLADRIBINE10 milligram
- ประเภทควบคุม
- ยาควบคุมพิเศษ
- ข้อบ่งใช้
- Mavenclad is indicated as a single disease modifying therapy for the treatment of adult patients with highly active relapsing-remitting multiple sclerosis (MS) as defined by clinical or imaging features. Mavenclad is generally recommend in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis. Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. Re-initiation of the therapy after year 4 has not been studied.
- รหัส ATC
- L01BB04 (CLADRIBINE)
ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ
- Category
- ยาสำเร็จรูป
- Trade name
- —
- Company / Manufacturer
- บริษัท เมอร์ค จำกัดดำเนินกิจการ
- Juristic registration number
- 0105534019122
- Producer's other permits
- See all permits held by this company →
A matching registration number confirms the registration exists — it does not verify that the physical item you hold is genuine. Always compare the product and manufacturer names on the label.
Last updated: 2026-07-29 · Data aggregated from official government databases: NBTC · FDA · TISI · DBD · Dept. of Tourism · ACFSReport incorrect data